Table 1.
Number and percentage of non-MenB isolates killed in hSBA by adolescent 4CMenB-elicited immune sera at different bactericidal titers in the Euro-3 and Brazilian panels, by serogroup and time point
| hSBA titers | MenC | MenW | MenY | All | ||||
|---|---|---|---|---|---|---|---|---|
| Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | Pre-vac | Post-vac | |
| Euro-3 panel | N = 76 | N = 28 | N = 23 | N = 127 | ||||
| ≥ 1:4 | 2 (2.6) | 40 (52.6) | 4 (14.3) | 20 (71.4) | 5 (21.7) | 15 (65.2) | 11 (8.7) | 75 (59.1) |
| ≥ 1:8 | 0 (0.0) | 33 (43.4) | 3 (10.7) | 20 (71.4) | 3 (13.0) | 15 (65.2) | 6 (4.7) | 68 (53.5) |
| ≥ 1:16 | 0 (0.0) | 28 (36.8) | 3 (10.7) | 20 (71.4) | 2 (8.7) | 14 (60.9) | 5 (3.9) | 62 (48.8) |
| ≥ 1:32 | 0 (0.0) | 25 (32.9) | 2 (7.1) | 19 (67.9) | 1 (4.3) | 9 (39.1) | 3 (2.4) | 53 (41.7) |
| ≥ 1:64 | 0 (0.0) | 23 (30.3) | 1 (3.6) | 15 (53.6) | 1 (4.3) | 6 (26.1) | 2 (1.6) | 44 (34.6) |
| ≥ 1:128 | 0 (0.0) | 17 (22.4) | 0 (0.0) | 12 (42.9) | 1 (4.3) | 2 (8.7) | 1 (0.8) | 31 (24.4) |
| Brazilian panel | N = 4 | N = 7 | N = 9 | N = 20 | ||||
| ≥ 1:4 | 0 (0.0) | 4 (100) | 0 (0.0) | 6 (85.7) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 16 (80.0) |
| ≥ 1:8 | 0 (0.0) | 4 (100) | 0 (0.0) | 6 (85.7) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 16 (80.0) |
| ≥ 1:16 | 0 (0.0) | 4 (100) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 15 (75.0) |
| ≥ 1:32 | 0 (0.0) | 3 (75.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 14 (70.0) |
| ≥ 1:64 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 6 (66.7) | 0 (0.0) | 11 (55.0) |
| ≥ 1:128 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (71.4) | 0 (0.0) | 4 (44.4) | 0 (0.0) | 9 (45.0) |
Data are presented as number and percentage of isolates killed in hSBA at the indicated titer
Men meningococcal serogroup, hSBA serum bactericidal antibody assay using human complement, N number of strains tested in hSBA with the 4CMenB-elicited immune sera, pre-vac pre-vaccination, post-vac post-vaccination (post-dose 2)